Understand the source comparison
SS-LUP-332 Alternatives 2026 Best: Metabolic Pathway Comparison
Survodutide GLP-1/glucagon dual agonist Indirect via glucagon-driven hepatic oxidation 46% hepatic steatosis reduction (Phase 2 biopsy data) Phase 3 trials ongoing Best functional substitute for researchers prioritising substrate oxidation and metabolic flexib
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Survodutide
- GLP-1/glucagon dual agonist
- Indirect via glucagon-driven hepatic oxidation
- 46% hepatic steatosis reduction (Phase 2 biopsy data)
- Phase 3 trials ongoing
- Best functional substitute for researchers prioritising substrate oxidation and metabolic flexibility
- Mazdutide
- GLP-1/glucagon co-agonist
- Glucagon pathway enhancement of FAO enzymes
- 22% increase in fasted fat oxidation rate (indirect calorimetry)
- Phase 2 complete, advancing to Phase 3
- Strong alternative for studies requiring measurable shifts in RQ (respiratory quotient)
- Tesofensine
- Monoamine reuptake inhibitor
- Thermogenic beta-adrenergic signalling
- 6% resting energy expenditure increase (Phase 2)
- Phase 3 halted (commercial), research use permitted
- Ideal for CNS-mediated metabolic studies where transcriptional mechanisms aren't the focus
- MK-677
- Ghrelin receptor agonist (growth hormone secretagogue)
- GH-mediated mitochondrial function enhancement
- Lean mass preservation during caloric deficit (indirect FAO effect)
- Not FDA-approved, widely available research-grade
- Best for studies combining metabolic outcomes with muscle preservation
- CJC-1295/Ipamorelin
- GHRH analogue + selective ghrelin agonist
- Growth hormone pathway activation
- Modest lipolytic effect; primary benefit is nitrogen retention
- Research compounds, not approved for clinical use
- Suitable for endurance and body composition studies where anabolic signalling is relevant